Clinical Trial Update: Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin Lymphoma [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating loncastuximab tesirine in combination with venetoclax for relapsed or refractory non-Hodgkin lymphoma is currently active but not rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Loncastuximab tesirine (loncastuximab tesirine)
• Venetoclax (venetoclax)

Snippet

Sponsor: Paolo Caimi, MD | Conditions: Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING